Stage II Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
Conditions
Brief summary
This phase II trial studies how well ofatumumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and dexamethasone alternating with ofatumumab in combination with cytarabine and methotrexate works in treating patients with newly diagnosed mantle cell lymphoma (MCL). Monoclonal antibodies, such as ofatumumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, dexamethasone, cytarabine, and methotrexate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ofatumumab together with alternating regimens of combination chemotherapy may kill more cancer cells.
Detailed description
PRIMARY OBJECTIVES: I. To determine the overall response rate (ORR), and in particular, the complete remission rate (CRR) in previously untreated MCL treated with ofatumumab in combination with aggressive chemo-immunotherapy. SECONDARY OBJECTIVES: I. To determine the high sensitivity flow cytometry (HSFCM) complete remission rate (HSFCM-CRR) in previously untreated MCL treated with ofatumumab in combination with aggressive chemo-immunotherapy +/- high dose chemotherapy and autologous stem cell transplant (HDC-ASCT). II. To determine the time-to-progression (TTP), progression-free survival (PFS) and overall survival (OS) of patients with previously untreated MCL treated with ofatumumab and aggressive chemoimmunotherapy +/- HDC-ASCT. III. To determine the toxicity profiles of ofatumumab in combination with high dose cytarabine chemoimmunotherapy +/- HDC-ASCT. IV. To correlate minimal residual disease (MRD) at different time intervals with TTP, PFS, and OS. V. To correlate surface cluster of differentiation (CD)20 levels, Ki67, and additional cytogenetic abnormalities in pretreatment tumor biopsies with respect to ORR, CRR, TTP, PFS, or OS. VI. To determine the relationship between proliferation signature and clinical outcome using quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR). VII. To determine changes in surface CD20 levels, Ki67, or gain of additional cytogenetic abnormalities in relapsed/refractory tumor specimens. VIII. To correlate serum component (C)3, C4, and hemolytic complement (CH)50 levels measured at baseline and at the end of first ofatumumab infusion with ORR, CRR, median response rate (MRR), TTP, PFS and OS. IX. Evaluate the ability of the induction and consolidation therapy to get 70% of patients to autologous stem cell transplantation. X. Evaluate the tolerability and CD34+ cell yield following therapy with patient and hyper-fractionated cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and dexamethasone (HyperCVAD)/high-dose cytarabine and methotrexate (HD-MA). XI. To compare differences in response rate in patients with MCL treated with ofatumumab + HyperCVAD/HD-MA according Cheson and Modified Cheson Criteria. OUTLINE: COURSES 1, 3, and 5 (O-HyperCVAD): Patients receive ofatumumab intravenously (IV) on day 1, cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5, doxorubicin hydrochloride IV continuously over 72 hours on days 6-8, vincristine sulfate IV on days 6 and 13, and dexamethasone IV or orally (PO) on days 3-6 and 13-16. COURSES 2, 4, and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1, methotrexate IV continuously over 24 hours on day 3, and cytarabine IV over 2 hours every 12 hours on days 4-5. Treatment repeats every 21 days for 6\* courses in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo standard high dose chemotherapy and autologous stem cell transplant (HDC-ASCT). Patients achieving a high sensitivity flow cytometry complete remission (HSFCM-CR) after 2 courses may proceed to HDC-ASCT after completing 4 courses of treatment. After completion of study treatment, patients are followed up every 4 months for 2 years, every 6 months for 3 years, and then as clinically instructed.
Interventions
PROCEDUREAutologous Hematopoietic Stem Cell Transplantation
Undergo autologous HDC-ASCT
DRUGCyclophosphamide
Given IV
DRUGCytarabine
Given IV
DRUGDexamethasone
Given IV or PO
DRUGDoxorubicin Hydrochloride
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGMethotrexate
Given IV
BIOLOGICALOfatumumab
Given IV
DRUGVincristine Sulfate
Given IV
Sponsors
National Comprehensive Cancer Network
Roswell Park Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Histologically documented mantle cell lymphoma with co-expression of CD20 and CD5 and lack of CD23 expression by immunophenotyping and at least one of the following confirmatory tests: 1) positive immunostaining for cyclin D1; 2) the presence of t(11;14) on cytogenetic analysis; OR 3) molecular evidence of B-cell leukemia/lymphoma 1 (bcl-1)/immunoglobulin heavy locus (IgH) rearrangement * Cases that are CD5-negative and/or CD23-positive will be eligible provided that the histopathology is consistent with mantle cell lymphoma AND positive for cyclin D1, t(11;14), or bcl-1/IgH rearrangement * A tissue block or unstained slides (10 - 20 slides) will be submitted to the Roswell Park Cancer Institute (RPCI) Pathology Department for central pathology review * A diagnosis based on peripheral blood or bone marrow aspirate is allowed; if the diagnosis is based only on blood, in addition to the immunophenotype and molecular confirmation above, a peripheral blood smear must be available for central pathology review; if the diagnosis is based on a bone marrow, the bone marrow core biopsy or aspirate clot tissue block will be submitted to the RPCI Pathology Department: if the tissue block is not available please submit the diagnostic smears for review * Extent of disease: stage I - IV; patients with nodular histology mantle cell lymphoma must have Ann Arbor stage III or IV disease to be eligible * Patients with mantle zone type histology will not be eligible * Patients with other mantle cell histologies are eligible regardless of stage * Measurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm\^2 in bidimensional measurement) * No active central nervous system (CNS) disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma; a lumbar puncture demonstrating mantle cell lymphoma at the time of registration to this study is not an exclusion for study enrollment * Patients must be previously untreated * No prior radiation therapy for mantle cell lymphoma * \>= 2 weeks since major surgery * No known hypersensitivity to murine products * No medical condition requiring chronic use of high dose systemic corticosteroids (i.e., doses of prednisone higher than 10 mg/day or equivalent) * No human immunodeficiency virus (HIV) infection; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; patients who test positive or who are known to be infected are not eligible; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at risk * Non-pregnant and non-nursing; women and men of reproductive potential should agree to use an effective means of birth control * Patients who test positive for hepatitis C antibody (Ab) are eligible provided all of the following criteria are met: 1) total bilirubin =\< 2 x upper limit of normal; 2) AND aspartate aminotransferase (AST) =\< 3 x upper limit of normal; AND 3) liver biopsy (pathology) demonstrates =\< grade 2 fibrosis and no cirrhosis * Specific guidelines will be followed regarding inclusion of MCL based on hepatitis B serological testing as follows: * Hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) negative, hepatitis B surface antibody (HBsAb) positive MCL patients are eligible * Patients who test positive for HBsAg are ineligible (regardless of other hepatitis B serologies) * For MCL patients with HBsAg negative, but HBcAb positive (regardless of HBsAb status), should have hepatitis B virus (HBV) deoxyribonucleic acid (DNA) testing done and protocol eligibility determined as follows: * If HBV DNA is positive the subject is excluded * If HBV DNA is negative, patient may be included but must undergo at least every 2 months HBV DNA polymerase chain reaction (PCR) testing from the start of treatment throughout the duration the study * Monitoring during the study is required at least every 2 months and during follow-up at a minimum of every 2-3 months up to 6 months after the last dose * Prophylactic antiviral therapy with lamivudine (3TC) or investigator's preferred antiviral regimen throughout protocol therapy and for 6-12 months thereafter may be initiated at the discretion of the investigator * If the patients' HBV DNA becomes positive during the study, the investigator should manage the clinical situation as per the standard of care of participating institution; the investigator should weigh the risks and benefits of continuing ofatumumab or discontinuing ofatumumab before appropriate treatment decisions are made for that individual patient * Patients must not have a history of cardiac disease, defined as New York Heart Association class II or greater or clinical evidence of congestive heart failure (CHF) * No known hypersensitivity to ofatumumab, humanized antibodies or chemotherapy agents throughout the protocol * Left ventricular ejection fraction (LVEF) by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) \>= 45% * Neutrophils \> 1000/uL * Platelets \>= 75,000/uL (unless significant bone marrow involvement with MCL) * Creatinine =\< 2.0 mg/dL * Total bilirubin =\< 2.0 mg/dL (unless MCL related or attributable to Gilbert's disease) * Urine or serum beta-human chorionic gonadotropin (HCG) or serum HCG = negative (if female patient of childbearing potential) * Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure * Consult with a physician experience in care and management of subjects with hepatitis B to manage/treat subjects who are anti-hepatitis B core antibody (HBc) positive
Exclusion criteria
* Prior history of HIV-positivity (routine HIV testing is not required pre-treatment) * Positive serology for hepatitis B (HB) defined as a positive test for HBsAg; in addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a hepatitis B DNA test will be performed and if positive the patient will be excluded * Serious non-malignant disease (e.g., active uncontrolled bacterial, viral, or fungal infections) or other medical conditions (including psychiatric) which, in the opinion of the Principal Investigator (PI) would compromise other protocol objectives * Presence of symptomatic CNS lymphoma * Pregnant or lactating females * Prior history of radiation or chemotherapy for MCL * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or other agents used in study * Patients with a currently active second malignancy, other than non-melanoma skin cancer or in situ carcinoma of the cervix or breast; patients are not considered to have a currently active malignancy if they have completed anti-cancer therapy, are considered by their physician to be at less than 30% risk of relapse and at least 2-5 years have lapsed * Major surgery, other than diagnostic surgery, within 2 weeks * Patients with non-Hodgkin lymphoma (NHL) other than MCL * Patients must not have a history of cardiac disease, defined as New York Heart Association class II or greater or clinical evidence of congestive heart failure; all patients must have a MUGA scan or 2-dimensional (D) echocardiogram indicating an ejection fraction of \>= 45% within 42 days prior to registration; the method used at baseline must be used for later monitoring * Unwilling or unable to follow protocol requirements * Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug * Received an investigational agent within 30 days prior to enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients Experiencing a Complete Response | 22 weeks | Evaluated according to the International Working Group Response criteria as reported by Cheson et al. and the revised Cheson criteria. Complete response is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Typically FDG-avid lymphoma: in patients with PET scan positive before therapy, a posttreatment residual mass of any size is permitted as long as it is PET negative. Variably FDG-avid lymphomas/FDG avidity unknown: in patients with a negative pretreatment PET scan, all lymph nodes and nodal masses must have regressed on CT to normal size (1.5 cm in their greatest transverse diameter for nodes 1.5 cm before therapy). Previously involved nodes that were 1.1 cm to 1.5 cm in their long axis and more than 1) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Percentage of Cells Positive for Ki67 | Baseline and up to 3 years | Mean change from baseline in Percentage of Cells Positive for Ki67 by patient response. |
| Median of Serum Complement CD20 Levels | Baseline | Median serum C20 MFI (mean fluorescence intensity) |
| Number of Participants With at Least One Serious Adverse Event | Up to 3 years | Evaluated using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. |
| Minimal Residual Disease (MRD) in Peripheral Blood Samples | Up to 3 years | Minimal residual disease (MRD) in peripheral blood samples at baseline. |
| Minimal Residual Disease (MRD) in Bone Marrow Biopsy/Aspiration Samples | Up to 3 years | Minimal residual disease (MRD) in and bone marrow biopsy/aspiration samples at baseline. |
| Percentage of Participants With Autologous Stem Cell Transplantation | Up to 6 weeks after the last dose of ofatumumab-chemotherapy, an average of 4 month | Estimated using simple relative frequencies. The corresponding 95% confidence intervals will be computed using the method proposed in Clopper and Pearson. |
| Median Progression-free Survival (PFS) | From baseline through study completion, an average of 5 years | Estimated distributions obtained using the Kaplan-Meier method. Estimates of quantities such as median survival will be obtained. Corresponding confidence intervals using the methodology of Brookmeyer and Crowley will be computed. |
| Proliferation Signature Using Quantitative Real-time RT-PCR | Baseline | Relationship between proliferation signature and clinical outcome will be compared using the log-rank test. Cox proportional hazards model regression will be utilized for multivariate analyses. |
| Proportion of Patients Who Experience Complete Remission as Assessed by HSFCM | Up to 3 years | Established when all CR criteria are met and negative flow cytometry examination of peripheral blood and bone marrow biopsy/aspiration collected at baseline, before courses 3 and 5, within 3 weeks after course 6, on day 100 (if HDC-ASCT eligible), and then every 6 months for 3 years. |
| Time-to-tumor Progression (TTP) at 3 Years | From baseline until objective tumor progression, as assessed up to 3 years | Estimated percentage of patients that progressed at 3 years. Time to Progression distributions obtained using the Kaplan-Meier method. Corresponding confidence intervals using the methodology of Brookmeyer and Crowley will be computed. |
| Median Overall Survival (OS) | From baseline through study completion, an average of 5 years | Estimated distributions obtained using the Kaplan-Meier method. Estimates of quantities such as median survival will be obtained. Corresponding confidence intervals using the methodology of Brookmeyer and Crowley will be computed. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) COURSES 1, 3, and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1, cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5, doxorubicin hydrochloride IV continuously over 72 hours on days 6-8, vincristine sulfate IV on days 6 and 13, and dexamethasone IV or PO on days 3-6 and 13-16.
COURSES 2, 4, and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1, methotrexate IV continuously over 24 hours on day 3, and cytarabine IV over 2 hours every 12 hours on days 4-5.
All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Eligible patients then undergo standard HDC-ASCT.
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous HDC-ASCT
Cyclophosphamide: Given IV
Cytarabine: Given IV
Dexamethasone: Given IV or PO
Doxorubicin Hydrochloride: Given IV
Laboratory Biomarker Analysis: Correlative studies
Methotrexate: Given IV
Ofatumumab: Given IV
Vincristine Sulfate: Given IV | 37 |
| Total | 37 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 2 |
Baseline characteristics
| Characteristic | Treatment (Monoclonal Antibody and Combination Chemotherapy) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 5 Participants |
| Age, Categorical Between 18 and 65 years | 32 Participants |
| Age, Continuous | 57.8 years STANDARD_DEVIATION 7.7 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 35 Participants |
| Sex: Female, Male Female | 10 Participants |
| Sex: Female, Male Male | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 16 / 37 |
| other Total, other adverse events | 37 / 37 |
| serious Total, serious adverse events | 19 / 37 |
Outcome results
Primary
Proportion of Patients Experiencing a Complete Response
Evaluated according to the International Working Group Response criteria as reported by Cheson et al. and the revised Cheson criteria. Complete response is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Typically FDG-avid lymphoma: in patients with PET scan positive before therapy, a posttreatment residual mass of any size is permitted as long as it is PET negative. Variably FDG-avid lymphomas/FDG avidity unknown: in patients with a negative pretreatment PET scan, all lymph nodes and nodal masses must have regressed on CT to normal size (1.5 cm in their greatest transverse diameter for nodes 1.5 cm before therapy). Previously involved nodes that were 1.1 cm to 1.5 cm in their long axis and more than 1)
Time frame: 22 weeks
Population: All treated and eligible patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Proportion of Patients Experiencing a Complete Response | .62 Proportion of participants |
Secondary
Change From Baseline in Percentage of Cells Positive for Ki67
Mean change from baseline in Percentage of Cells Positive for Ki67 by patient response.
Time frame: Baseline and up to 3 years
Population: All treated and eligible patients that had samples taken after baseline
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Change From Baseline in Percentage of Cells Positive for Ki67 | Not CR | -2.5 percentage of cells positive for Ki-67 | Standard Deviation 10.6 |
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Change From Baseline in Percentage of Cells Positive for Ki67 | CR | NA percentage of cells positive for Ki-67 | — |
Secondary
Median of Serum Complement CD20 Levels
Median serum C20 MFI (mean fluorescence intensity)
Time frame: Baseline
Population: All treated and evaluable patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Median of Serum Complement CD20 Levels | 186.8 mean fluorescence intensity |
Secondary
Median Overall Survival (OS)
Estimated distributions obtained using the Kaplan-Meier method. Estimates of quantities such as median survival will be obtained. Corresponding confidence intervals using the methodology of Brookmeyer and Crowley will be computed.
Time frame: From baseline through study completion, an average of 5 years
Population: All treated and eligible patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Median Overall Survival (OS) | 56.0 months |
Secondary
Median Progression-free Survival (PFS)
Estimated distributions obtained using the Kaplan-Meier method. Estimates of quantities such as median survival will be obtained. Corresponding confidence intervals using the methodology of Brookmeyer and Crowley will be computed.
Time frame: From baseline through study completion, an average of 5 years
Population: All treated and eligible patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Median Progression-free Survival (PFS) | 45.5 months |
Secondary
Minimal Residual Disease (MRD) in Bone Marrow Biopsy/Aspiration Samples
Minimal residual disease (MRD) in and bone marrow biopsy/aspiration samples at baseline.
Time frame: Up to 3 years
Population: All treated and eligible patients with available samples
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Minimal Residual Disease (MRD) in Bone Marrow Biopsy/Aspiration Samples | Negative | 6 Participants |
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Minimal Residual Disease (MRD) in Bone Marrow Biopsy/Aspiration Samples | Postive | 24 Participants |
Secondary
Minimal Residual Disease (MRD) in Peripheral Blood Samples
Minimal residual disease (MRD) in peripheral blood samples at baseline.
Time frame: Up to 3 years
Population: All treated and eligible patients with available samples
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Minimal Residual Disease (MRD) in Peripheral Blood Samples | Negative | 2 Participants |
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Minimal Residual Disease (MRD) in Peripheral Blood Samples | Postive | 29 Participants |
Secondary
Number of Participants With at Least One Serious Adverse Event
Evaluated using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Time frame: Up to 3 years
Population: All treated and eligible patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Number of Participants With at Least One Serious Adverse Event | 19 Participants |
Secondary
Percentage of Participants With Autologous Stem Cell Transplantation
Estimated using simple relative frequencies. The corresponding 95% confidence intervals will be computed using the method proposed in Clopper and Pearson.
Time frame: Up to 6 weeks after the last dose of ofatumumab-chemotherapy, an average of 4 month
Population: All treated and eligible patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Percentage of Participants With Autologous Stem Cell Transplantation | 73 percentage of participants |
Secondary
Proliferation Signature Using Quantitative Real-time RT-PCR
Relationship between proliferation signature and clinical outcome will be compared using the log-rank test. Cox proportional hazards model regression will be utilized for multivariate analyses.
Time frame: Baseline
Population: Samples were not viable due to inadequate tissue.
Secondary
Proportion of Patients Who Experience Complete Remission as Assessed by HSFCM
Established when all CR criteria are met and negative flow cytometry examination of peripheral blood and bone marrow biopsy/aspiration collected at baseline, before courses 3 and 5, within 3 weeks after course 6, on day 100 (if HDC-ASCT eligible), and then every 6 months for 3 years.
Time frame: Up to 3 years
Population: All treated and eligible patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Proportion of Patients Who Experience Complete Remission as Assessed by HSFCM | .84 Proportion of participants |
Secondary
Time-to-tumor Progression (TTP) at 3 Years
Estimated percentage of patients that progressed at 3 years. Time to Progression distributions obtained using the Kaplan-Meier method. Corresponding confidence intervals using the methodology of Brookmeyer and Crowley will be computed.
Time frame: From baseline until objective tumor progression, as assessed up to 3 years
Population: All treated and eligible patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Monoclonal Antibody and Combination Chemotherapy) | Time-to-tumor Progression (TTP) at 3 Years | 76 percentage of participants |